Orexo AB (publ) Logo

Orexo AB (publ)

ORXOF

(0.0)
Stock Price

1,08 USD

-12.92% ROA

-359.08% ROE

-6.69x PER

Market Cap.

534.147.255,69 USD

1962.4% DER

0% Yield

-17.67% NPM

Orexo AB (publ) Stock Analysis

Orexo AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Orexo AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Orexo AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Orexo AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Orexo AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Orexo AB (publ) Revenue
Year Revenue Growth
2002 2.961.000
2003 21.360.000 86.14%
2004 86.715.000 75.37%
2005 62.352.000 -39.07%
2006 131.956.000 52.75%
2007 76.757.000 -71.91%
2008 233.346.000 67.11%
2009 236.104.000 1.17%
2010 210.499.000 -12.16%
2011 199.614.000 -5.45%
2012 326.278.000 38.82%
2013 429.355.000 24.01%
2014 570.316.000 24.72%
2015 646.200.000 11.74%
2016 705.800.000 8.44%
2017 643.700.000 -9.65%
2018 783.100.000 17.8%
2019 844.800.000 7.3%
2020 663.600.000 -27.31%
2021 565.000.000 -17.45%
2022 624.300.000 9.5%
2023 63.049.560 -890.17%
2024 616.000.000 89.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Orexo AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2002 12.503.000
2003 30.319.000 58.76%
2004 64.011.000 52.63%
2005 -64.789.000 198.8%
2006 94.512.000 168.55%
2007 155.972.000 39.4%
2008 238.125.000 34.5%
2009 222.258.000 -7.14%
2010 161.120.000 -37.95%
2011 194.411.000 17.12%
2012 216.174.000 10.07%
2013 238.144.000 9.23%
2014 197.822.000 -20.38%
2015 172.600.000 -14.61%
2016 132.300.000 -30.46%
2017 134.200.000 1.42%
2018 166.800.000 19.54%
2019 181.300.000 8%
2020 224.900.000 19.39%
2021 272.300.000 17.41%
2022 318.000.000 14.37%
2023 303.100.000 -4.92%
2024 257.200.000 -17.85%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Orexo AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 6.708.000
2003 12.871.000 47.88%
2004 24.224.000 46.87%
2005 0 0%
2006 52.335.000 100%
2007 58.932.000 11.19%
2008 55.294.000 -6.58%
2009 307.827.000 82.04%
2010 46.819.000 -557.48%
2011 49.561.000 5.53%
2012 82.589.000 39.99%
2013 126.373.000 34.65%
2014 113.026.000 -11.81%
2015 141.500.000 20.12%
2016 161.600.000 12.44%
2017 96.100.000 -68.16%
2018 166.700.000 42.35%
2019 139.600.000 -19.41%
2020 102.800.000 -35.8%
2021 151.500.000 32.15%
2022 202.300.000 25.11%
2023 124.300.000 -62.75%
2024 168.800.000 26.36%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Orexo AB (publ) EBITDA
Year EBITDA Growth
2002 21.340.000
2003 26.578.000 19.71%
2004 15.483.000 -71.66%
2005 73.945.000 79.06%
2006 -32.959.000 324.35%
2007 -172.811.000 80.93%
2008 -103.229.000 -67.41%
2009 -94.215.000 -9.57%
2010 -46.552.000 -102.39%
2011 -108.031.000 56.91%
2012 -57.959.000 -86.39%
2013 -92.370.000 37.25%
2014 -19.137.000 -382.68%
2015 -99.900.000 80.84%
2016 71.200.000 240.31%
2017 47.700.000 -49.27%
2018 129.500.000 63.17%
2019 288.400.000 55.1%
2020 16.800.000 -1616.67%
2021 -141.300.000 111.89%
2022 -74.100.000 -90.69%
2023 -12.663.210 -485.16%
2024 -800.000 -1482.9%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Orexo AB (publ) Gross Profit
Year Gross Profit Growth
2002 1.299.000
2003 18.842.000 93.11%
2004 84.785.000 77.78%
2005 65.306.000 -29.83%
2006 120.805.000 45.94%
2007 62.373.000 -93.68%
2008 215.900.000 71.11%
2009 212.454.000 -1.62%
2010 184.178.000 -15.35%
2011 170.617.000 -7.95%
2012 298.403.000 42.82%
2013 400.010.000 25.4%
2014 462.874.000 13.58%
2015 496.000.000 6.68%
2016 556.200.000 10.82%
2017 479.300.000 -16.04%
2018 611.300.000 21.59%
2019 739.200.000 17.3%
2020 598.000.000 -23.61%
2021 486.100.000 -23.02%
2022 521.700.000 6.82%
2023 54.275.130 -861.21%
2024 467.600.000 88.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Orexo AB (publ) Net Profit
Year Net Profit Growth
2002 -20.803.000
2003 -27.593.000 24.61%
2004 -15.944.000 -73.06%
2005 -43.249.000 63.13%
2006 -32.943.000 -31.28%
2007 -172.597.000 80.91%
2008 -103.054.000 -67.48%
2009 -98.079.000 -5.07%
2010 -89.246.000 -9.9%
2011 -392.009.000 77.23%
2012 -85.863.000 -356.55%
2013 -154.936.000 44.58%
2014 -56.584.000 -173.82%
2015 -210.000.000 73.06%
2016 29.000.000 824.14%
2017 23.200.000 -25%
2018 137.900.000 83.18%
2019 219.100.000 37.06%
2020 -84.400.000 359.6%
2021 -223.500.000 62.24%
2022 -177.600.000 -25.84%
2023 -12.663.210 -1302.49%
2024 -143.600.000 91.18%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Orexo AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -831
2003 -981 15.31%
2004 -451 -117.78%
2005 -3 -14900%
2006 -2 -50%
2007 -11 81.82%
2008 -5 -175%
2009 -4 0%
2010 -4 -33.33%
2011 -14 78.57%
2012 -3 -600%
2013 -5 60%
2014 -2 -400%
2015 -6 83.33%
2016 1 0%
2017 1 0%
2018 4 100%
2019 6 50%
2020 -2 400%
2021 -7 66.67%
2022 -5 -20%
2023 0 0%
2024 -4 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Orexo AB (publ) Free Cashflow
Year Free Cashflow Growth
2002 -429.000
2003 -433.000 0.92%
2004 -1.120.000 61.34%
2005 -45.382.000 97.53%
2006 -22.285.000 -103.64%
2007 -202.068.000 88.97%
2008 -103.161.000 -95.88%
2009 -136.515.000 24.43%
2010 -46.405.000 -194.18%
2011 -121.964.000 61.95%
2012 22.901.000 632.57%
2013 -370.706.000 106.18%
2014 -559.023.000 33.69%
2015 -113.200.000 -393.84%
2016 154.800.000 173.13%
2017 145.000.000 -6.76%
2018 238.400.000 39.18%
2019 255.000.000 6.51%
2020 -172.900.000 247.48%
2021 -281.800.000 38.64%
2022 -180.500.000 -56.12%
2023 -114.200.000 -58.06%
2024 -9.100.000 -1154.95%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Orexo AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2002 0
2003 0 0%
2004 0 0%
2005 -45.382.000 100%
2006 -17.672.000 -156.8%
2007 -152.750.000 88.43%
2008 -101.490.000 -50.51%
2009 -133.927.000 24.22%
2010 -42.967.000 -211.7%
2011 -117.228.000 63.35%
2012 28.668.000 508.92%
2013 -263.201.000 110.89%
2014 -487.300.000 45.99%
2015 -109.200.000 -346.25%
2016 156.200.000 169.91%
2017 146.600.000 -6.55%
2018 242.000.000 39.42%
2019 287.000.000 15.68%
2020 16.800.000 -1608.33%
2021 -229.000.000 107.34%
2022 -156.600.000 -46.23%
2023 -95.000.000 -64.84%
2024 -6.500.000 -1361.54%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Orexo AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2002 429.000
2003 433.000 0.92%
2004 1.120.000 61.34%
2005 0 0%
2006 4.613.000 100%
2007 49.318.000 90.65%
2008 1.671.000 -2851.41%
2009 2.588.000 35.43%
2010 3.438.000 24.72%
2011 4.736.000 27.41%
2012 5.767.000 17.88%
2013 107.505.000 94.64%
2014 71.723.000 -49.89%
2015 4.000.000 -1693.08%
2016 1.400.000 -185.71%
2017 1.600.000 12.5%
2018 3.600.000 55.56%
2019 32.000.000 88.75%
2020 189.700.000 83.13%
2021 52.800.000 -259.28%
2022 23.900.000 -120.92%
2023 19.200.000 -24.48%
2024 2.600.000 -638.46%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Orexo AB (publ) Equity
Year Equity Growth
2002 25.517.000
2003 35.882.000 28.89%
2004 79.436.000 54.83%
2005 338.909.000 76.56%
2006 324.350.000 -4.49%
2007 671.252.000 51.68%
2008 569.783.000 -17.81%
2009 548.661.000 -3.85%
2010 468.237.000 -17.18%
2011 311.101.000 -50.51%
2012 191.194.000 -62.71%
2013 161.459.000 -18.42%
2014 467.900.000 65.49%
2015 270.100.000 -73.23%
2016 310.300.000 12.96%
2017 329.100.000 5.71%
2018 476.100.000 30.88%
2019 706.400.000 32.6%
2020 558.500.000 -26.48%
2021 349.600.000 -59.75%
2022 193.900.000 -80.3%
2023 58.900.000 -229.2%
2024 24.200.000 -143.39%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Orexo AB (publ) Assets
Year Assets Growth
2002 33.248.000
2003 45.152.000 26.36%
2004 106.017.000 57.41%
2005 371.310.016 71.45%
2006 379.932.000 2.27%
2007 801.873.000 52.62%
2008 702.025.000 -14.22%
2009 649.334.000 -8.11%
2010 712.691.000 8.89%
2011 546.101.000 -30.51%
2012 481.755.000 -13.36%
2013 772.330.000 37.62%
2014 1.238.800.000 37.65%
2015 1.020.000.000 -21.45%
2016 1.018.800.000 -0.12%
2017 1.003.900.000 -1.48%
2018 1.286.700.000 21.98%
2019 1.501.100.000 14.28%
2020 1.232.900.000 -21.75%
2021 1.273.700.000 3.2%
2022 1.109.000.000 -14.85%
2023 786.600.000 -40.99%
2024 773.300.000 -1.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Orexo AB (publ) Liabilities
Year Liabilities Growth
2002 7.731.000
2003 9.270.000 16.6%
2004 26.581.000 65.13%
2005 4.746.000 -460.07%
2006 55.582.000 91.46%
2007 130.621.000 57.45%
2008 132.242.000 1.23%
2009 100.673.000 -31.36%
2010 244.454.000 58.82%
2011 235.000.000 -4.02%
2012 290.561.000 19.12%
2013 610.871.000 52.43%
2014 770.900.000 20.76%
2015 749.900.000 -2.8%
2016 708.500.000 -5.84%
2017 674.800.000 -4.99%
2018 810.600.000 16.75%
2019 794.700.000 -2%
2020 674.400.000 -17.84%
2021 924.100.000 27.02%
2022 915.100.000 -0.98%
2023 727.700.000 -25.75%
2024 749.100.000 2.86%

Orexo AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.5
Net Income per Share
-2.32
Price to Earning Ratio
-6.69x
Price To Sales Ratio
1.15x
POCF Ratio
-10.72
PFCF Ratio
-8.71
Price to Book Ratio
22.11
EV to Sales
1.88
EV Over EBITDA
196.55
EV to Operating CashFlow
-17.58
EV to FreeCashFlow
-14.31
Earnings Yield
-0.15
FreeCashFlow Yield
-0.11
Market Cap
0,53 Bil.
Enterprise Value
0,88 Bil.
Graham Number
6.05
Graham NetNet
-11.06

Income Statement Metrics

Net Income per Share
-2.32
Income Quality
0.64
ROE
-1.35
Return On Assets
-0.15
Return On Capital Employed
-0.12
Net Income per EBT
1.02
EBT Per Ebit
1.97
Ebit per Revenue
-0.09
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.32
Research & Developement to Revenue
0.58
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.78
Operating Profit Margin
-0.09
Pretax Profit Margin
-0.17
Net Profit Margin
-0.18

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.45
Free CashFlow per Share
-1.78
Capex to Operating CashFlow
-0.23
Capex to Revenue
0.02
Capex to Depreciation
0.14
Return on Invested Capital
-0.11
Return on Tangible Assets
-0.13
Days Sales Outstanding
201.78
Days Payables Outstanding
562.67
Days of Inventory on Hand
335.95
Receivables Turnover
1.81
Payables Turnover
0.65
Inventory Turnover
1.09
Capex per Share
0.33

Balance Sheet

Cash per Share
4,05
Book Value per Share
0,70
Tangible Book Value per Share
-3.77
Shareholders Equity per Share
0.7
Interest Debt per Share
14.41
Debt to Equity
19.62
Debt to Assets
0.61
Net Debt to EBITDA
76.9
Current Ratio
1.77
Tangible Asset Value
-0,13 Bil.
Net Current Asset Value
-0,28 Bil.
Invested Capital
455700000
Working Capital
0,20 Bil.
Intangibles to Total Assets
0.2
Average Receivables
0,25 Bil.
Average Payables
0,10 Bil.
Average Inventory
70450000
Debt to Market Cap
0.89

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Orexo AB (publ) Dividends
Year Dividends Growth

Orexo AB (publ) Profile

About Orexo AB (publ)

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

CEO
Mr. Nikolaj Sorensen
Employee
113
Address
P.O. Box 303
Uppsala, 751 05

Orexo AB (publ) Executives & BODs

Orexo AB (publ) Executives & BODs
# Name Age
1 Mr. Fredrik Jarrsten
Executive Vice President & Chief Financial Officer
70
2 Mr. Nikolaj Sorensen
President & Chief Executive Officer
70
3 Mr. Robert A. Deluca
President of Orexo US Inc
70
4 Mr. Jesper Lind
Advisor
70
5 Ms. Cecilia Coupland
Senior Vice President & Head of Operations
70
6 Lena Wange
Investor Relations & Communications Director
70
7 Mr. Robert Ronn
Senior Vice President and Head of R&D
70
8 Dr. Edward Kim M.B.A., M.D.
Chief Medical Officer
70

Orexo AB (publ) Competitors